Drug Profile
Research programme: inner ear disorders therapies - DURECT/NeuroSystec
Latest Information Update: 26 Mar 2012
Price :
$50
*
At a glance
- Originator DURECT Corporation
- Developer DURECT Corporation; NeuroSystec Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Tinnitus
Most Recent Events
- 02 Mar 2012 Discontinued - Preclinical for Tinnitus in USA (unspecified route)
- 10 Jul 2007 Preclinical development is ongoing
- 12 Jul 2004 Preclinical trials in Tinnitus in USA (unspecified route)